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Available online 07 February 2019To our knowledge, there are no reports of status epilepticus (SE) associated with mitochondrial diseases and
treated with perampanel (PER). We present three cases of patients with refractory SE associated with MELAS
syndrome who responded favorably to PER.
All caseswere diagnosed as non-convulsive SE (focal without impairment of level of consciousness). After an ini-
tial treatmentwith other anti-seizure drugs, PERwas added in all cases (8, 16 and 12mg) and cessation of SEwas
observed within the next 4-8 hours. All the cases involved a stroke-like lesion present on brain MRI.
In our patients, PER was an effective option in SE associated with MELAS syndrome.21, 08035 Barcelona
na).
. This is an open acce©2019 TheAuthors. Published by Elsevier Inc. This is an open access article under the CCBY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Epilepsy is commonly described in mitochondrial diseases. The
types of epilepsy reported in both adults and children include myo-
clonic seizures, focal to bilateral tonic–clonic seizures, epilepsia partialis
continua, and generalized epilepsy syndromes [1–3]. The prevalence of
status epilepticus (SE) in these patients is unknown and it is reported
less often than other types of seizures, although itmay go unrecognized.
Within the spectrum of mitochondrial diseases, MELAS (mitochon-
drial encephalopathy with lactic acidosis and stroke-like episodes)
is among those most commonly associated with SE. It was reported in
7.9% of cases in one series, and always in the context of a stroke-like
episode [4].
Most SE episodes in mitochondrial diseases are refractory to treat-
ment [2], and status persists despite administration of anti-seizure
drugs (ASDs). In this scenario, the efficacy of GABA-ergic drugs is
markedly reduced [5] and glutamate can play a major role in SE persis-
tence by promoting perpetuation of the epileptic activity through AMPA
receptors.
Perampanel (PER) is a selective, noncompetitive AMPA receptor
antagonist that has emerged as a promising option for SE because of
its particular pharmacodynamics. Knowledge on its use for managing
SE is increasing [6] and a recent review of all published SE cases treated, Spain.
ss article underwith PER has described highly variable efficacy. The review included 10
articles with 69 SE episodes [6], in which none of the causes was
mitochondrial diseases. Here, we describe the first series of cases in
which patients with mitochondrial disorders experienced SE and
received PER treatment.2. Case studies
2.1. Case 1
A 37-year-old man was admitted to our hospital for repetitive focal
seizures with an occipital semiology. His history included genetically-
confirmed MELAS syndrome (mtDNA m.3243ANG) with epilepsy,
treated with lamotrigine (LTG). The electroencephalography (EEG)
performed in the emergency department included lateralized periodic
discharges with superimposed fast activity and rhythmic activity
(LPDs + FR); and according to the ILAE classification [7], he was
considered to have a non-convulsive SE (NCSE) without prominent
motor symptoms (i.e., without coma, focal, and without impaired
consciousness).
The patient was started on levetiracetam (LEV) and lacosamide
(LCM) with no clinical or EEG improvement. L-Arginine, coenzyme
Q10, andweight-adjustedmethylprednisolonewere then given succes-
sively in the first 24 h. As SE persisted, PER was added directly at 8 mg,
without therapy escalation as has been done in other reports [6]. Six
hours later, the patient had improved clinically, and an EEGmonitoringthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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of SE, the patient underwent magnetic resonance imaging (MRI),
showing a hyperintense area in the right occipital lobe consistent
with metabolic infarction (Fig. 1). Hospitalization lasted 11 days
with no need for intensive care unit (ICU) admission (Table 1), and
recovery was favorable.
2.2. Case 2
A 19-year-old male who had epilepsy and known MELAS since
childhood, (genetically confirmed: mtDNAm.3243ANG), was admit-
ted to the emergency room for headache, photopsia, and loss of vi-
sion in the left visual hemifield. He was receiving LTG and
clobazam to treat the epilepsy. The EEG showed an evolving ictal pat-
tern in the right occipital region progressing in amplitude, morphol-
ogy, and degree of sharpness, with sequential spread. This pattern
was consistent with NCSE similar to the first patient. L-Arginine, co-
enzyme Q10, and weight-adjusted methylprednisolone were
started. Clonazepam (CLZ) and LEV were the first drugs adminis-
tered, followed by LCM. As there was no improvement, PER was ad-
ministered at a dose of 16 mg without escalation. At 8 h following
the start of PER, the EEG showed resolution of SE. MRI depicted a
hyperintense area in the right occipital lobe consistent with a meta-
bolic infarction. The duration of hospital stay was 60 days. This
lengthy stay was not related to SE, but instead, to systemic problems
associated with his underlying illness. ICU was not needed, and he
was discharged with moderate disability (Table 1).
2.3. Case 3
A 39-year-oldmanwas admitted for continuous visual symptoms in
right hemifield. His history included a stroke-like lesion one year before
causing a symptomatic epilepsy; he was diagnosed as MELAS during
follow-up and he was being treated with LEV. Emergent EEG findings
indicated non-convulsive SE with visual symptoms (occipital origin)
and its features included LPDs + FR, similar to the findings in Case 1.
L-Arginine and coenzyme Q10 were also started at admission. LCM
was added to LEV with no clinical or EEG improvement. After
confirming the lack of response, oral PER 12 mg was directly added to
the treatment. SE resolved in the following 4 h, was verified with EEG,
and nomore clinical seizureswere reported by the patient. A new lesion
found on MRI was consistent with a stroke-like lesion associated with
MELAS. The hospital stay lasted 6 days and recovery was excellent.
3. Discussion
We present a favorable experience with PER in the treatment of
three cases of SE in patients with mitochondrial disorders. Information
on patients with refractory SE treated with PER is increasing, but
still limited, and there are no published data on its use in mitochondrial
disorders. To our knowledge, these are thefirst cases of SE due to stroke-
like lesions in MELAS treated with PER.
SE occurring in patients with mitochondrial disorders is usually
resistant to anti-seizure drug treatment. In stroke-like lesions, clinical
symptoms and EEG usually shows involvement of posterior brain re-
gions, and the prognosis may be poor, with liver dysfunction and
death [8]. Treatment of SE in mitochondrial disease has not been defin-
itively validated [8], and there may be a limit to the therapy options, as
many anti-seizure drugs used in SE pose a risk forMELAS syndrome and
therefore, should be avoided or carefullymonitored [9]. Examples of po-
tentially risky anti-seizure drugs are benzodiazepines, phenobarbital,
propofol, and valproate, which can lead to worsening of seizures and
even multi-system damage.
Furthermore, recommendations are not straightforward for
treating NCSE without impaired consciousness. In adults with NCSEindependent of MELAS, after failure of a benzodiazepine (first-line
therapy), an ASD is recommended as second-line therapy, and fur-
ther non-anesthetic ASDs such as levetiracetam, phenobarbital, or
valproic acid is recommended instead of intravenous anesthetics
[10]. Therefore, this treatment uncertainty plus restrictions for the
use of certain ASDs in MELAS may considerably reduce the available
therapeutic strategies.
In our three patients, SE was confirmed by EEG, and SE cessation
was established by clinical and EEG resolution of the previously doc-
umented ictal activity. A combination of several ASDs was used to
treat refractory SE; hence, it may be difficult to establish a relation-
ship between PER monotherapy and success in terminating the epi-
sode. However in our report, PER was the last drug introduced or
increased in the 24 h prior to SE cessation, with no changes in con-
comitant medication; and this method is considered as the most ap-
propriate measure for the evaluation of efficacy of an AED in the
treatment of SE [11].
PER was well tolerated, with no adverse events recorded. Fur-
thermore, oral administration enabled conservative management
of SE associated with a stroke-like episode. Another point to consider
is that it may be difficult to determine whether the improvement
was related to other aspects of the treatment (e.g., L-Arginine or
Q10 coenzyme administration), nonetheless, this concomitant treat-
ment had been started before the ASDs, and there had been no
response.
We cannot draw firm conclusions based on only three cases. It could
be argued that the response may have been due to spontaneous resolu-
tion of a stroke-like episode or delayed effects of the previously admin-
istered anti-seizure medication. However, after use of 2 or 3 ASDs in
refractory NCSE, the next step would be to consider use of anesthetics
and intubation, and these cases show that PER could be an option to
avoid the use of drugs already restricted in this group of patients. An-
other reason to use PER is that SE was refractory and long-lasting in
all cases, and it is known that as epileptiform activity persists, SE be-
comes more resistant to GABAergic drugs, which could make drugs
targeting AMPA receptors more appropriate. Of note, PER use was
only directed to treat SE and was not used to treat the stroke-like
episodes.4. Conclusion
Management of patientswithMELAS syndrome is difficult and there
is no standardized treatment for the management of focal SE. Once
stroke-like episodes begin, the clinical status of the patient may rapidly
decline andmultiorgan dysfunction can occur; hence, the importance of
treating the epilepsy. The findings in our cases indicate that PERmay be
an effective option in SE associated with MELAS syndrome. Formal
clinical trials in patients with various genetic causes of mitochondrial
epilepsy would be the ideal method to ascertain the true efficacy of
PER in these patients.Conflict of interest
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Table 1
Patients' clinical data.
Patient 1 Patient 2 Patient 3
Age, years 37 19 39
Preexisting epilepsy Yes Yes Yes
Etiology Stroke-like
episode
Stroke-like
episode
Stroke-like
episode
SE type NCSE without
coma, focal
NCSE without
coma, focal
NCSE without
coma, focal
EEG pattern LPD + F + R Evolving,
electrographic
seizures
Evolving,
electrographic
seizures
STESS score 1 0 0
EMSE score 81 68 74
Initial dose PER, mg 8 16 12
Maximum dose PER, mg 8 16 12
GOSE scale Good
recovery (7)
Moderate
disability (5)
Good
recovery (7)
ICU stay No No No
Hospital stay, days 11 60 6
Drugs used LEV, LCM, PER CLZ, LEV, LCM,
PER
LEV, LCM, PER
Abbreviations. NCSE, non-convulsive status epilepticus; LPD, lateralized periodic
discharges; +F+R, superimposed fast and rhythmic activity; AEDs, antiepileptic drugs;
LEV, levetiracetam; LCM, lacosamide; PER, perampanel; CLZ: clonazepam; STESS, Status
Epilepticus Severity Score; EMSE, Epidemiology-basedMortality Score in Status Epilepticus;
GOSE, Glasgow Outcome Scale-Extended; ICU: Intensive Care Unit.
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